is in discussions with the Indian government
seeking an “expedited approval
pathway” for its Covid-19 vaccine
, its CEO Albert Bourla
said on LinkedIn on Monday, announcing a donation of medicines
worth more than $70 million.
“Unfortunately, our vaccine is not registered in India although our application was submitted months ago,” he said.
“We are currently discussing with the Indian government an expedited approval pathway to make our Pfizer-BioNTech vaccine available for use in the country.”
Follow and connect with us on , Facebook